FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2599681969> ?p ?o ?g. }

• W2599681969 endingPage "4018" @default.
• W2599681969 startingPage "4018" @default.
• W2599681969 abstract "4018 Background: CPT-11 showed modest activity and tolerability in MPA. We developed a new strategy to improve efficacy and tolerability of CPT-11 based regimen in MPA pts. Methods: Chemotherapy-naive pts with histologically proven MPA, bilirubin levels < 1.5 ULN and performance status (PS) 0-1 were randomized in a phase II trial to receive either FOLFIRI.3 (CPT-11 90 mg/m 2 as a 60-min infusion on day (D) 1, leucovorin 400 mg/m 2 as a 2-hr infusion on day 1, followed by 5-FU 2000 mg/m 2 as a 46-hr infusion and CPT-11 90 mg/m 2 , repeated on D3, at the end of the 5-FU infusion, every 2 weeks) for 2 months alternarting with G (1000 mg/m² at a fixed dose rate of 10 mg/m²/min on D1, D8, D15, D29, D36 and D43) for 2 months (arm A) or G alone (arm B). Using Fleming design the primary end point was rate of progression free survival (PFS) at 6 months from (H0) 25% over (H1) 45% needing to include 49 pts/arm. Results: Between 2007 and 2011, 98 pts were enrolled (males: 59, median age: 62 years, PS 0: 32%). Median follow-up was 23 months. Grade 3-4 toxicities per pts (%) in arm A/B were diarrhea 13/0, nausea-vomiting 11/4, neutropenia 51/25 and febrile neutropenia 4/0. No toxic death occurred. Response rate were 40 and 11% as disease control rate (CR+PR+SD) were 73 and 52% in arm A and B, respectively. The primary endpoint of the trial was met with rate of PFS at 6 months of 48% (95% CI: 33-63) in arm A while in arm B PFS was 30% (95% CI: 17 - 44). One year PFS was 23% (95%CI: 11.5-36) and 11% (95%CI: 4-21), respectively. Conclusions: FIRGEM strategy is feasible and efficient with a manageable toxicity profile in good condition pts with MPA. A phase III trial comparing this strategy with the FOLFIRINOX triplet therapy focusing on quality of life should now be performed." @default.
• W2599681969 created "2017-04-07" @default.
• W2599681969 creator A5003820025 @default.
• W2599681969 creator A5008947885 @default.
• W2599681969 creator A5010475231 @default.
• W2599681969 creator A5017132355 @default.
• W2599681969 creator A5024180743 @default.
• W2599681969 creator A5033663279 @default.
• W2599681969 creator A5040985815 @default.
• W2599681969 creator A5041770520 @default.
• W2599681969 creator A5042218927 @default.
• W2599681969 creator A5045892999 @default.
• W2599681969 creator A5050400319 @default.
• W2599681969 creator A5058660922 @default.
• W2599681969 creator A5064556770 @default.
• W2599681969 creator A5064596403 @default.
• W2599681969 creator A5065957948 @default.
• W2599681969 creator A5070426915 @default.
• W2599681969 creator A5074133896 @default.
• W2599681969 creator A5083396561 @default.
• W2599681969 date "2012-05-20" @default.
• W2599681969 modified "2023-09-23" @default.
• W2599681969 title "FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM." @default.
• W2599681969 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.4018" @default.
• W2599681969 hasPublicationYear "2012" @default.
• W2599681969 type Work @default.
• W2599681969 sameAs 2599681969 @default.
• W2599681969 citedByCount "6" @default.
• W2599681969 countsByYear W25996819692012 @default.
• W2599681969 countsByYear W25996819692013 @default.
• W2599681969 countsByYear W25996819692014 @default.
• W2599681969 countsByYear W25996819692015 @default.
• W2599681969 countsByYear W25996819692018 @default.
• W2599681969 crossrefType "journal-article" @default.
• W2599681969 hasAuthorship W2599681969A5003820025 @default.
• W2599681969 hasAuthorship W2599681969A5008947885 @default.
• W2599681969 hasAuthorship W2599681969A5010475231 @default.
• W2599681969 hasAuthorship W2599681969A5017132355 @default.
• W2599681969 hasAuthorship W2599681969A5024180743 @default.
• W2599681969 hasAuthorship W2599681969A5033663279 @default.
• W2599681969 hasAuthorship W2599681969A5040985815 @default.
• W2599681969 hasAuthorship W2599681969A5041770520 @default.
• W2599681969 hasAuthorship W2599681969A5042218927 @default.
• W2599681969 hasAuthorship W2599681969A5045892999 @default.
• W2599681969 hasAuthorship W2599681969A5050400319 @default.
• W2599681969 hasAuthorship W2599681969A5058660922 @default.
• W2599681969 hasAuthorship W2599681969A5064556770 @default.
• W2599681969 hasAuthorship W2599681969A5064596403 @default.
• W2599681969 hasAuthorship W2599681969A5065957948 @default.
• W2599681969 hasAuthorship W2599681969A5070426915 @default.
• W2599681969 hasAuthorship W2599681969A5074133896 @default.
• W2599681969 hasAuthorship W2599681969A5083396561 @default.
• W2599681969 hasConcept C126322002 @default.
• W2599681969 hasConcept C141071460 @default.
• W2599681969 hasConcept C168563851 @default.
• W2599681969 hasConcept C197934379 @default.
• W2599681969 hasConcept C203092338 @default.
• W2599681969 hasConcept C2776694085 @default.
• W2599681969 hasConcept C2777063308 @default.
• W2599681969 hasConcept C2778375690 @default.
• W2599681969 hasConcept C2779804826 @default.
• W2599681969 hasConcept C2780258809 @default.
• W2599681969 hasConcept C2780456651 @default.
• W2599681969 hasConcept C2781413609 @default.
• W2599681969 hasConcept C71924100 @default.
• W2599681969 hasConcept C90924648 @default.
• W2599681969 hasConceptScore W2599681969C126322002 @default.
• W2599681969 hasConceptScore W2599681969C141071460 @default.
• W2599681969 hasConceptScore W2599681969C168563851 @default.
• W2599681969 hasConceptScore W2599681969C197934379 @default.
• W2599681969 hasConceptScore W2599681969C203092338 @default.
• W2599681969 hasConceptScore W2599681969C2776694085 @default.
• W2599681969 hasConceptScore W2599681969C2777063308 @default.
• W2599681969 hasConceptScore W2599681969C2778375690 @default.
• W2599681969 hasConceptScore W2599681969C2779804826 @default.
• W2599681969 hasConceptScore W2599681969C2780258809 @default.
• W2599681969 hasConceptScore W2599681969C2780456651 @default.
• W2599681969 hasConceptScore W2599681969C2781413609 @default.
• W2599681969 hasConceptScore W2599681969C71924100 @default.
• W2599681969 hasConceptScore W2599681969C90924648 @default.
• W2599681969 hasIssue "15_suppl" @default.
• W2599681969 hasLocation W25996819691 @default.
• W2599681969 hasOpenAccess W2599681969 @default.
• W2599681969 hasPrimaryLocation W25996819691 @default.
• W2599681969 hasRelatedWork W1836187181 @default.
• W2599681969 hasRelatedWork W2127026223 @default.
• W2599681969 hasRelatedWork W2160354293 @default.
• W2599681969 hasRelatedWork W2364146720 @default.
• W2599681969 hasRelatedWork W2373190357 @default.
• W2599681969 hasRelatedWork W2518765238 @default.
• W2599681969 hasRelatedWork W2590180764 @default.
• W2599681969 hasRelatedWork W3000244458 @default.
• W2599681969 hasRelatedWork W3030105578 @default.
• W2599681969 hasRelatedWork W3207791950 @default.
• W2599681969 hasVolume "30" @default.
• W2599681969 isParatext "false" @default.
• W2599681969 isRetracted "false" @default.
• W2599681969 magId "2599681969" @default.

• next